Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine
AffiliationUniv Arizona, Dept Surg, Div Urol
Univ Arizona, Dept Cellular & Mol Med
MetadataShow full item record
PublisherCIG MEDIA GROUP, LP
CitationBatai, K., Bergersen, A., Price, E., Hynes, K., Ellis, N. A., & Lee, B. R. (2018). Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine. Clinical genitourinary cancer, 16(3), e535-e541. https://doi.org/10.1016/j.clgc.2018.01.006
JournalCLINICAL GENITOURINARY CANCER
Rights© 2018 Elsevier Inc. All rights reserved.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractCancer disparities in Native Americans (NAs) and Hispanic Americans (HAs) vary significantly in terms of cancer incidence and mortality rates across geographic regions. This review reports that kidney and renal pelvis cancers are unevenly affecting HAs and NAs compared to European Americans of non-Hispanic origin, and that currently there is significant need for improved data and reporting to be able to advance toward genomic-based precision medicine for the assessment of such cancers in these medically underserved populations. More specifically, in states along the US-Mexico border, HAs and NAs have higher kidney cancer incidence rates as well as a higher prevalence of kidney cancer risk factors, including obesity and chronic kidney disease. They are also more likely to receive suboptimal care compared to European Americans. Furthermore, they are underrepresented in epidemiologic, clinical, and molecular genomic studies of kidney cancer. Therefore, we maintain that progress in precision medicine for kidney cancer care requires an understanding of various factors among HAs and NAs, including the real kidney cancer burden, variations in clinical care, issues related to access to care, and specific clinical and molecular characteristics.(C) 2018 Elsevier Inc. All rights reserved.
Note12 month embargo; published online: 12 February 2018
VersionFinal accepted manuscript
SponsorsAmerican Cancer Society [IRG-16-124-37-IRG]